Drug Metabolism and Pharmacokinetics

A special issue of Pharmaceutics (ISSN 1999-4923).

Deadline for manuscript submissions: closed (30 April 2015) | Viewed by 9317

Special Issue Editor


E-Mail Website
Guest Editor
Department of Pharmaceutical Sciences, College of Pharmacy, University of South Florida, Tampa, FL 33612, USA
Interests: drug discovery; systems pharmacology; cancer pharmacology; drug metabolism and transport; pharmacometrics; pharmacogenomics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue, “Drug Metabolism and Pharmacokinetics”, will address the main aspects of drug metabolism and the pharmacokinetics of new and existing drugs. In drug development, Absorption, Distribution, Metabolism, and Excretion (ADME) are some of the most important aspects of a drug that a scientist must know of. The topics of papers submitted to this Special Issue can be about drug methods, models, and their applications, drug mechanisms, regulation (of drugs) by both genetic and epigenetic factors, and the clinical and toxicological data concerning drug metabolism and pharmacokinetic studies. Translational and clinical studies on important drug metabolizing enzymes and drug transporters will also be considered.

Prof. Dr. Shufeng Zhou
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • drug metabolism
  • pharmacokinetics
  • regulation
  • cytochrome P450
  • drug transporter
  • drug-drug interaction
  • toxicity
  • drug response
  • metabolic pathway
  • molecular modeling
  • drug development

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

1330 KiB  
Article
Influence of Differing Analgesic Formulations of Aspirin on Pharmacokinetic Parameters
by Kunal Kanani, Sergio C. Gatoulis and Michael Voelker
Pharmaceutics 2015, 7(3), 188-198; https://doi.org/10.3390/pharmaceutics7030188 - 3 Aug 2015
Cited by 22 | Viewed by 8663
Abstract
Aspirin has been used therapeutically for over 100 years. As the originator and an important marketer of aspirin-containing products, Bayer’s clinical trial database contains numerous reports of the pharmacokinetics of various aspirin formulations. These include evaluations of plain tablets, effervescent tablets, granules, chewable [...] Read more.
Aspirin has been used therapeutically for over 100 years. As the originator and an important marketer of aspirin-containing products, Bayer’s clinical trial database contains numerous reports of the pharmacokinetics of various aspirin formulations. These include evaluations of plain tablets, effervescent tablets, granules, chewable tablets, and fast-release tablets. This publication seeks to expand upon the available pharmacokinetic information concerning aspirin formulations. In the pre-systemic circulation, acetylsalicylic acid (ASA) is rapidly converted into its main active metabolite, salicylic acid (SA). Therefore, both substances are measured in plasma and reported in the results. The 500 mg strength of each formulation was chosen for analysis as this is the most commonly used for analgesia. A total of 22 studies were included in the analysis. All formulations of 500 mg aspirin result in comparable plasma exposure to ASA and SA as evidenced by AUC. Tablets and dry granules provide a consistently lower Cmax compared to effervescent, granules in suspension and fast release tablets. Effervescent tablets, fast release tablets, and granules in suspension provide a consistently lower median Tmax compared to dry granules and tablets for both ASA and SA. This report reinforces the importance of formulation differences and their impact on pharmacokinetic parameters. Full article
(This article belongs to the Special Issue Drug Metabolism and Pharmacokinetics)
Show Figures

Graphical abstract

Back to TopTop